B*44 restricted peptides for use in immunotherapy against cancers and related methods

Patent metadata

Field	Value
Publication number	US-11014972-B2
Application number	US-202017117964-A
Country	US
Kind code	B2
Filing date	Dec 10, 2020
Priority date	Sep 17, 2018
Publication date	May 25, 2021
Grant date	May 25, 2021

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

First claim

The invention claimed is:

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of RELVHMINW (SEQ ID NO: 35),
wherein the activated T cells are cytotoxic T cells produced by contacting T cells in vitro with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cells,
wherein the cancer is breast cancer, uterine cancer, or endometrial cancer.

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

6. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.

7. The method of claim 1 , wherein the antigen presenting cell is a dendritic cell or a macrophage.

8. The method of claim 1 , wherein the contacting is in the presence of an anti-CD28 antibody and IL-12.

9. The method of claim 1 , wherein the cancer is breast cancer.

10. The method of claim 1 , wherein the cancer is uterine cancer or endometrial cancer.

11. The method of claim 5 , wherein the adjuvant is IL-2.

12. The method of claim 5 , wherein the adjuvant is IL-7.

13. The method of claim 5 , wherein the adjuvant is IL-12.

14. The method of claim 5 , wherein the adjuvant is IL-15.

15. The method of claim 5 , wherein the adjuvant is IL-21.

16. A method of treating a patient who has breast cancer, uterine cancer, or endometrial cancer, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, wherein said peptide consists of the amino acid sequence of RELVHMINW (SEQ ID NO: 35), thereby inducing a T-cell response to the breast cancer, the uterine cancer, or the endometrial cancer.

17. The method of claim 16 , wherein the cancer is breast cancer.

18. The method of claim 16 , wherein the cancer is uterine cancer or endometrial cancer.

19. The method of claim 16 , wherein the pharmaceutically acceptable salt is chloride salt.

20. The method of claim 16 , wherein the pharmaceutically acceptable salt is acetate salt.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Song Colette
• Schuster Heiko
• Kowalewski Daniel Johannes
• Schoor Oliver
• Fritsche Jens
• Weinschenk Toni
• Singh Harpreet

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• C12N5/0636

  T lymphocytes · CPC title

• A61K39/0011

  Cancer antigens · CPC title

• A61K35/17

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title